Last updated: March 3, 2026
What is NDC 69367-0412?
NDC 69367-0412 refers to Nulibry (Fosdenopterin), a drug approved by the FDA in September 2021 for the treatment of recurrence prevention in patients with molybdenum cofactor deficiency (MoCD) type A. It is a specialty medication with a development and commercialization profile focused on ultra-rare conditions. Nulibry operates within a niche market, primarily targeting a small patient population.
Market Size and Therapeutic Landscape
Patient Population Estimates
MoCD type A is an ultra-rare genetic disorder characterized by severe neurological impairment. The overall prevalence is estimated at less than 1 case per million live births, with only a few dozen confirmed cases globally.
| Metric |
Data |
| Estimated U.S. Patients |
10 – 20 (based on rarity and incidence rates) |
| Global Patients |
Fewer than 100-200 |
Current Treatment Landscape
There are no approved treatments for MoCD type A. Nulibry is the first therapy approved specifically for this condition, giving it a first-mover advantage in this niche market.
Market Drivers
- Unmet medical need: No existing approved treatments encourage adoption once access and awareness are established.
- Pricing transparency and reimbursement: Reimbursement policies for ultra-rare disease drugs typically involve patient assistance programs, high drug prices, and specialty-care billing codes.
- Regulatory incentives: Orphan drug designation allows for seven years of market exclusivity in the U.S.
Pricing Analysis
Initial Pricing
The wholesale acquisition cost (WAC) for Nulibry was set at $950,000 annually per patient upon FDA approval, reflecting typical pricing for ultra-rare disease therapies.
| Parameter |
Value |
| WAC |
$950,000/year |
| Cost per vial |
$70,000 (approximate, based on dosing units) |
| Dosing frequency |
Multiple infusions per week over several months |
Pricing Benchmarks
Comparative analysis with other orphan drugs:
| Drug |
Indication |
WAC |
Year of Approval |
Market-Exclusive Period |
| Nulibry (Fosdenopterin) |
MoCD Type A |
$950,000 |
2021 |
2028 |
| Zolgensma |
Spinal muscular atrophy |
$2.1 million |
2019 |
2028 |
| Spinraza |
SMA |
$750,000 first year |
2016 |
2023 |
Pricing reflects the high development costs, small patient pools, and R&D investments associated with orphan drugs.
Revenue Projections
Assuming maximal uptake:
| Year |
Estimated Patients Treated |
Revenue (USD) |
Notes |
| 2023 |
10 |
$9.5 million |
Minimal initial penetration |
| 2024 |
15 |
$14.25 million |
Growing awareness, expanding access |
| 2025 |
20 |
$19 million |
Stable market share |
Given the rarity, annual revenues remain limited but could increase with broader diagnosis and expanded indications.
Market Dynamics and Challenges
Adoption Barriers
- Limited awareness among clinicians
- High-cost burden for payers
- Logistic challenges of infusion-based therapy in rare diseases
Competitive Threats
- No direct competitors currently exist
- Off-label or future pipeline therapies are unlikely, given the ultra-rare nature
Regulatory and Reimbursement Environment
- Innovative payment models, such as outcomes-based agreements, could influence price adjustments
- Orphan drug status provides market exclusivity until 2028 in the U.S.
Outlook and Price Projection
Anticipated price stability through 2028 due to exclusivity. Potential for incremental price increases tied to inflation and manufacturing costs. Post-exclusivity, generic or biosimilar development remains unlikely due to the complexity and limited market.
Summary
| Key Data Point |
Value |
| Initial WAC |
$950,000 yearly |
| Patient estimates |
10–20 in the U.S. |
| Market size |
Extremely small; under 200 patients globally |
| Revenue potential (2023-2025) |
$10–$20 million annually |
Limited by disease rarity, the market outlook remains constrained but stable, driven mainly by pricing strategies and market exclusivity.
Key Takeaways
- NDC 69367-0412 (Nulibry) targets an ultra-rare disorder with a small but critical unmet need.
- Pricing is set at approximately $950,000 annually, aligning with other orphan drugs.
- Market size is minimal, with fewer than 20 patients expected in the U.S. annually.
- Revenue projections suggest $10–$20 million per year in the near term, subject to patient access and payer policies.
- Market exclusivity until 2028 supports stable pricing, but long-term growth depends on diagnosis rates and potential expansion.
FAQs
1. What factors influence the price of Nulibry?
Pricing considers the rarity of the disease, development costs, manufacturing complexity, and lack of competitors. Orphan drug policies grant market exclusivity, supporting high prices.
2. How many patients are estimated to receive Nulibry in the first three years?
Between 10 and 20 patients annually in the U.S., with a similar or slightly higher number globally.
3. What is the primary revenue driver for Nulibry?
High annual treatment costs coupled with a small patient population generate limited but steady revenue.
4. Are there competing therapies for MoCD Type A?
No approved alternatives exist, giving Nulibry a monopolistic position.
5. What are the key risks to revenue growth?
Limited patient diagnosis, reimbursement barriers, and potential for off-label or future therapies could restrict market expansion.
References
[1] U.S. Food and Drug Administration. (2021). FDA approves first drug for molybdenum cofactor deficiency. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-molybdenum-cofactor-deficiency
